Here's the reader question this primer answers: when a blockbuster biologic loses its core patent protection, what's left to defend? Regeneron's anti-VEGF eye franchise is a clean case study, and the patent record tells the story better than any earnings narrative.

Start with what the drug does. In diseases like wet age-related macular degeneration and diabetic retinopathy, the protein VEGF triggers leaky, abnormal blood vessels in the retina. Anti-VEGF drugs soak up VEGF so those vessels don't form. It works, it's a large market, and that success invites both biosimilar copies and direct competitors — which is exactly what the broader patent landscape shows.

“A method of treating an eye disorder in a patient that may include administering a medicament to the patient with a prefilled syringe, wherein the administration of the medicament with the prefilled syringe is configured to treat the eye disorder and decrease a rate of likelihood of an ocular infect…”— U.S. Patent No. 12,649,031 source

The competitive field is crowded, and the grants prove it. Novartis holds US12649781B2 on treating diabetic retinopathy with its own anti-VEGF antibody, brolucizumab. Kodiak Sciences holds US12643958B2 on methods of treating eye disorders. These are not Regeneron patents — they are rivals with issued claims in the same indication. The "no orphan claims" rule applies here: every one of these is a specific, verifiable grant by a named competitor.

So how does an incumbent defend a maturing franchise? Regeneron's 2026 grant US12649031B2, "Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation" (issued June 9, 2026), points to the answer: the device. A pre-filled syringe that reduces inflammation is a genuine clinical improvement and a fresh patent — one that a biosimilar of the molecule alone does not automatically inherit. The fight moves from the antibody to how the antibody gets into the eye.

This is a recurring pattern worth naming for the general reader. When the molecule's core protection erodes, defensible value migrates to the surrounding layers: formulation, dosing interval, and delivery hardware. A biosimilar can copy the active ingredient; it cannot necessarily copy a patented, inflammation-reducing injection system without infringing.

Read Regeneron's recent grants as a map of where the franchise is digging in. The core anti-VEGF idea is contested by Novartis, Kodiak, and biosimilar-makers. The newer Regeneron IP is increasingly about delivery and tolerability — the parts of the product a copycat can't simply replicate. That's the Eylea fight in one sentence: the molecule is commoditizing, so the company is patenting everything around it.